Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study (NCT06020716) | Clinical Trial Compass
RecruitingPhase 4
Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study
Norway350 participantsStarted 2023-08-16
Plain-language summary
The AMIC study is a double-blind, placebo-controlled, multicenter, nationwide, randomized controlled academic pharmaceutical trial.
OVERALL PRIMARY OBJECTIVES:
* To study the clinical efficacy of antibiotics in children with chronic wet cough (CWC).
* To study if duration of treatment with antibiotics in children with CWC has impact on efficacy or time to relapse of symptoms.
OVERALL SECONDARY OBJECTIVE:
-To study respiratory pathogens and the diversity/composition of airway and gut microbiome in children with CWC compared to healthy controls, and changes in pathogens/microbiome after treatment with antibiotics.
OVERALL TERTIARY OBJECTIVE:
-To study the role of inflammation, immunology, and genetics in children with chronic wet cough and suspicion of PBB to increase the knowledge of pathophysiological mechanisms associated with PBB.
The study will include two different RCTs AMIC 1 and AMIC 2:
AMIC 1:
Participants will be randomly assigned to 14 days amoxicillin-clavulanate syrup or placebo.
AMIC 2:
Participants will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup.
Who can participate
Age range9 Months – 36 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 9 and \< 36 months.
✓. Body weight ≥ 7 kg and \< 24 kg.
✓. Born term with Gestational age ≥ 37 weeks.
✓. Chronic wet cough for \> 4 weeks at screening and in addition average cough score last 7 days at randomization ≥ 4 points and without signs of another cause. Registration ≥ 5 days is mandatory.
✓. Written informed consent obtained from both parents at inclusion.
✓. The study subject must be assessed as eligible for treatment with Augmentin.
Exclusion criteria
✕. Gestational age \< 37 weeks.
✕. History of acute upper or lower airway infection the last 2 weeks.
✕. History of other viral or bacterial infections the last 2 weeks.
✕. Episode with temperature above 38 °C during the last 2 weeks.
What they're measuring
1
Response to treatment
Timeframe: Response to treatment will be assessed 14 days after end of antibiotic treatment